Summary

• ANI Pharmaceuticals is rated a speculative buy, with the investment thesis centered on Cortrophin Gel's rare disease revenue growth and transformation.
• Management guides to $540M-$575M Cortrophin revenue in 2026, making rare disease close to 60% of total revenue and supporting a re-rating.
• A $108 fair value is based on 9x 2026 adjusted EBITDA, offering ~30% upside if Cortrophin growth and gout expansion materialize as guided.
• Key risks include payer dynamics, Cortrophin concentration, and execution of the gout expansion, with current low multiples justified only if growth falters.
• Looking for a portfolio of ideas like this one? Members of The Total Pharma Tracker get exclusive access to our subscriber-only portfolios. Learn More »
• Sitewide Sale 2026: Get 20% Off

ANI Pharmaceuticals (ANIP) is a speculative Buy because you have to clearly understand what you are buying. You are not just buying a quarterly estimate beat, or a share repurchase or a one-time licensing fee. The

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.